The PG13 cell line was obtained by integrating a Moloney leukemia virus (MLV) expression vector and gibbon leukemia virus (GALV) membrane protein gene modification from mouse embryonic fibroblasts (NIH/3T3). PG13 cells, as a type of packaging cell, are currently mainly used in the development of cellular products such as CAR-T/TCR-T cells. Therefore, relevant biological products need to be tested for the content of residual DNA in PG13 cells.
This kit is equipped with PG13 DNA quantitative reference which can quickly and accurately quantitatively detect PG13 residual DNA in the intermediate, semi-finished and finished products of various biological products.
PG13-specific DNA reference standard for accurate residual DNA quantification
Validated for intermediates to final products (meets FDA/EMA guidelines)
Sensitive detection (≤10 pg/μL) of residual PG13 DNA in biologics
| Specification | 100 Reactions |
Assay range | 3.00×10¹~3.00×10⁵ fg/μL |
Limit of quantitation | 3 fg/μL |
Precision | CV%≤15 |
| Validity period | 18 months |
| Storage conditions | -20℃ |
| LOQ | 30 fg/μL |
| LOD | 3 fg/μL |
| Concentration (copies/μL) | Log10 Concentration | Ct Value(1) | Ct Value(2) | Ct Value(3) | Ct Mean Value | CV |
| 3.00E+05 | 5.48 | 12.14 | 12.15 | 12.22 | 12.17 | 0.37% |
| 3.00E+04 | 4.48 | 15.44 | 15.47 | 15.48 | 15.46 | 0.13% |
| 3.00E+03 | 3.48 | 18.77 | 18.81 | 18.93 | 18.84 | 0.44% |
| 3.00E+02 | 2.48 | 22.39 | 22.45 | 22.27 | 22.37 | 0.41% |
| 3.00E+01 | 1.48 | 25.67 | 25.68 | 25.86 | 25.74 | 0.42% |
| 3.00E+00 | 0.48 | 29.19 | 29.15 | 28.94 | 29.09 | 0.46% |
| Amplification efficiency | 98.63% | |||||
Standard curve:
86 198 5711 6962 
info@hillgene.com 
English
_20260106165102.webp "First-of-Its-Kind Fentanyl Vaccine Prepares to Enter Human Clinical Trials")
